Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer

Biotechnic and Histochemistry

Volumn 81, Issue 2-3, 2006, Pages 79-85

  Purnomosari, D ^a   Aryandono, T ^a   Setiaji, K ^a   Nugraha, S B ^a   Pals, G ^b   van Diest, P J ^c  

^a GADJAH MADA UNIVERSITY   (Indonesia)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Amplification; Breast cancer; HER 2 neu; MLPA; Polymerase chain reaction

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CANCER INVASION; CANCER PATIENT; CHROMOSOME 17; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DNA EXTRACTION; DNA PROBE; FEMALE; FROZEN SECTION; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCUS; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDONESIA; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTIPLEX LIGATION PROBE AMPLIFICATION; ONCOGENE NEU; POLYMERASE CHAIN REACTION; SAMPLE; SCORING SYSTEM;

BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR PROBES; POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2;

EID: 33747358366     PISSN: 10520295     EISSN: 14737760     Source Type: Journal    
DOI: 10.1080/10520290600822198     Document Type: Article

References (36)

1. Armour, JA and Sismani, C and Patsalis, PC and Cross, G. (2000) Measurement of locus copy number by hybridisation with amplifiable probes Nucl. Acids Res., 28, pp.605-609.
2. Baak, JPA and Chin, D and Van Diest, PJ and Matze-Cok, P and Bacus, SS. (1991) Comparative long term prognostic value of quantitative Her2/neu protein expression, DNA ploidy, morphometric and clinical features in paraffin-embedded invasive breast cancer Lab. Invest., 64, pp.215-222.
3. Bargmann, CI and Hung, MC and Weinberg, RA. (1986) The neu oncogene encodes an epidermal growth factor receptor-related protein Nature, 319, pp.226-230.
4. Birner, P and Oberhuber, G and Stani, J and Reithofer, C and Samonigg, H and Hausmaninger, H and Kubista, E and Kwasny, W and Kandioler-Eckersberger, D and Gnant, M and Jakesz, R. (2001) Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer Clin. Cancer Res., 7, pp.1669-1675.
5. Choi D.H. ShinDB, LeeMH, LeeDW, DhandapaniD, CarterD, KingBL, HafftyBG. A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer 98: 1587-1595.
6. Di Leo, A and Dowsett, M and Horten, B and Penault-Llorca, F. (2002) Current status of HER2 testing Oncology 63, pp.25-32.
7. Elledge, RM and Clark, GM and Chamness, GC and Osborne, CK. (1994) Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States J. Natl. Cancer Inst., 86, pp.705-712.
8. Ginestier, C and Charafe-Jauffret, E and Penault-Llorca, F and Geneix, J and Adelaide, J and Chaffanet, M and Mozziconacci, MJ and Hassoun, J and Viens, P and Birnbaum, D and Jacquemier, J. (2004) Comparative multi-methodological measurement of ERBB2 status in breast cancer J. Pathol., 202, pp.286-298.
9. Hanna, W. (2001) Testing for HER2 status Oncology, 61, pp.22-30.
10. Horiguchi, J and Iino, Y and Takei, H and Maemura, M and Koibuchi, Y and Takeyoshi, I and Ohwada, S and Yokoe, T and Nakajima, T and Oyama, T and Morishita, Y. (2000) Immunohistochemical study on primary and recurrent tumors in patients with local recurrence in the conserved breast Oncol. Rep., 7, pp.295-298.
11. Jacobs, TW and Gown, AM and Yaziji, H and Barnes, MJ and Schnitt, SJ. (2000) HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement Am. J. Clin. Pathol., 113, pp.251-258.
12. Jacobs, TW and Gown, AM and Yaziji, H and Barnes, MJ and Schnitt, SJ. (1999) Specificity of Herceptest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system J. Clin. Oncol., 17, pp.1983-1987.
13. Kallionemi, A and Kallionemi, O-P and Sudar, D and Rutovitz, D and Graw, JW and Waldman, F and Pinkel, D. (1992) Comparative Genomic Hybridization for molecular cytogenetic analysis of solid tumors Science, 258, pp.818-821.
14. Konecny, GE and Thomssen, C and Luck, HJ and Untch, M and Wang, HJ and Kuhn, W and Eidtmann, H and du Bois, A and Olbricht, S and Steinfeld, D and Mobus, V and von Minckwitz, G and Dandekar, S and Ramos, L and Pauletti, G and Pegram, MD and Janicke, F and Slamon, DJ. (2004) Her-2/ neu gene amplification and response to paclitaxel in patients with metastatic breast cancer J. Natl. Cancer Inst., 96, pp.1141-1151.
15. Lebeau, A and Deimling, D and Kaltz, C and Sendelhofert, A and Iff, A and Luthardt, B and Untch, M and Lohrs, U. (2001) Her-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization J. Clin. Oncol, 19, pp.354-363.
16. Mass, RD and Press, MF and Anderson, S and Murphy, M and Slamon, D. (2001) Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH) Proc. Am. Soc. Clin. Oncol., 20, pp.85.
17. Merchant, WJ and Millis, RR and Smith, P and Chaudary, MA and Barnes, DM. (1999) Expression of c-erbB2 and p53 protein is similar in breast cancer from British and Japanese women Int. J. Cancer, 84, pp.278-283.
18. Osaki, A and Toi, M and Yamada, H and Kawami, H and Kuroi, K and Toge, T. (1992) Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients Am. J. Surg., 164, pp.323-326.
19. Pauletti, G and Dandekar, S and Rong, H and Ramos, L and Peng, H and Seshadri, R and Slamon, DJ. (2000) Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry J. Clin. Oncol., 18, pp.3651-3664.
20. Penault-Llorca, F and Adelaide, J and Houvenaeghel, G and Hassoun, J and Birnbaum, D and Jacquemier, J. (1994) Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation J. Pathol., 173, pp. 65-75.
21. Perez, EA and Roche, PC and Jenkins, RB and Reynolds, CA and Halling, KC and Ingle, JN and Wold, LE. (2002) HER2 testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization Mayo Clin. Proc., 77, pp.148-154.
22. Popescu, NC and King, CR and Kraus, MH. (1989) Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32 Genomics, 4, pp.362-366.
23. Press, MF and Slamon, DJ and Flom, KJ and Park, J and Zhou, JY and Bernstein, L. (2002) Evaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens J. Clin. Oncol., 20, pp.3095-3105.
24. Rhodes, A and Jasani, B and Anderson, E and Dodson, AR and Balaton, AJ. (2002a) Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: A comparative study involving results from laboratories in 21 countries Am. J. Clin. Pathol., 118, pp.408-417.
25. Rhodes, A and Jasani, B and Couturier, J and McKinley, MJ and Morgan, JM and Dodson, AR and Navabi, H and Miller, KD and Balaton, AJ. (2002b) A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer Am. J. Clin. Pathol, 117, pp.81-89.
26. Ridolfi, RL and Jamehdor, MR and Arber, JM. (2000) HER-2/neu testing in breast carcinoma: A combined immunohistochemical and fluorescence in situ hybridization approach Mod. Pathol., 13, pp.866-873.
27. Roche, PC and Ingle, JN. (1999) Increased HER2 with U.S. Food and Drug Administration-approved antibody J. Clin. Oncol, 17, pp.434.
28. Schouten, JP and McElgunn, CJ and Waaijer, R and Zwijnenburg, D and Diepvens, F and Pals, G. (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification Nucl. Acids Res. 30, pp. e57.
29. Sellner, LN and Taylor, GR. (2004) MLPA and MAPH: New techniques for detection of gene deletions Hum. Mutat., 23, pp.413-419.
30. Slamon, DJ and Clark, GM and Wong, SG and Levin, WJ and Ullrich, A and McGuire, WL. (1987) Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene Science, 235, pp.177-182.
31. Slamon, DJ and Godolphin, W and Jones, LA and Holt, JA and Wong, SG and Keith, DE and Levin, WJ and Stuart, SG and Udove, J and Ullrich, A. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science, 244, pp.707-712.
32. Sparano, JA. (2001) Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials Semin. Oncol., 28, pp.20-27.
33. Tubbs, RR and Pettay, JD and Roche, PC and Stoler, MH and Jenkins, RB and Grogan, TM. (2001) Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message J. Clin. Oncol, 19, pp.2714-2721.
34. Van de Vijver, MJ and Peterse, JL and Mooi, WJ and Wisman, P and Lomans, J and Dalesio, O and Nusse, R. (1988) Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer N. Engl. J. Med., 319, pp.1239-1245.
35. Wright, C and Nicholson, S and Angus, B and Sainsbury, JR and Farndon, J and Cairns, J and Harris, AL and Horne, CH. (1992) Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer Br. J. Cancer, 65, pp.118-121.
36. Yokoda, T and Imamura, M and Teshima, S and Suzuki, H and Tezuka, F and Kikuchi, S and Kunii, Y and Yamauchi, H. (1999) c-erbB-2, p53 protein expression and steroid hormone receptors in breast carcinomas: An immunohistochemical study Anticancer Res., 19, pp.4007-4012.